IMP: BODs Resolution on holding 2018 AGM

On March 22, 2018, the Board of Directors of Imexpharm Corporation approved to hold the 2018 Annual General Meeting of Shareholders as follows:

1)    Approving the business plan in 2018 to submit the 2018 Annual General Meeting of Shareholders:

-          Total revenue: 1,400 billion dongs, increase 18.1% compared 2017;

-          Profit before tax & Technology and Science Decelopment Fund: 190 billion dong, increase 16.9% compared 2017.

2)    Approving the holding of Annual General Meeting 2018:

-          Record date: April 12, 2018;

-          Meeting date: April 28, 2018.

3)    Approving the content of Annual General Meeting 2018:

-          Report on the Board of Directors activities 2017 and plan for 2018;

-          Report from the Supervisory Board in 2017 and plan for 2018;

-          Business result in 2017 & business plan in 2018;

-          Remuneration of the Board of Directors & Supervisory Board in 2018;

-          Plan for profit distribution and dividend payment in 2017 & 2018;

-          Stock issuance to pay dividend for 2017;

-          Selection of Auditing company to audit financial statements in 2018;

-          Other issues.

HOSE

>   HCD: Changes in 5th Business Registration Certificate (26/03/2018)

>   HSG: Setting up 02 branches (26/03/2018)

>   IMP: Holding 2018 AGM (26/03/2018)

>   FPT: Document of 2018 AGM (26/03/2018)

>   LCM: Board resolution on holding Annual General Meeting 2018 (26/03/2018)

>   BCG: Board approves to receive the stake transfer (26/03/2018)

>   RAL: Resolution on holding 2018 AGM & cash dividend (26/03/2018)

>   PDR: Board approves to receive the stake transfer (26/03/2018)

>   HEM: Financial Statement FY 2017 (consolidated) (26/03/2018)

>   HEM: Financial Statement FY 2017 (holding company) (26/03/2018)